

Association Between Interleukin 1 Polymorphisms and Rheumatoid Arthritis Susceptibility: A Metaanalysis

YOUNG HO LEE, JONG DAE JI, and GWAN GYU SONG

ABSTRACT. *Objective.* To determine whether interleukin 1 (IL-1) polymorphisms confer susceptibility to rheumatoid arthritis (RA).

Methods. We conducted metaanalyses on associations between IL-1 polymorphisms and RA susceptibility, using fixed or random effects models.

Results. A total of 18 separate comparisons were made using 10 European, 7 Asian, and 1 Latin American population samples. Metaanalysis of the *IL-1B+3954* CC genotype revealed an association with RA in all subjects (odds ratio = 0.776, 95% confidence interval = 0.609–0.988, $p = 0.040$). In Asians, an association between *IL-1B+3954* and RA was identified. In contrast, no association was found between the *IL-1B+3954* polymorphism and RA susceptibility in European populations. Metaanalyses of the *IL-1B-511* and *IL-1RN VNTR* polymorphisms identified no association between these polymorphisms and RA.

Conclusion. Our metaanalysis shows that the *IL-1B+3954* polymorphism was associated with the development of RA, but only in Asians. (First Release Nov 1 2008; J Rheumatol 2009;36:12–15; doi:10.3899/jrheum.080450)

Key Indexing Terms:

INTERLEUKIN 1

GENETIC POLYMORPHISM

RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a chronic inflammatory disease that predominantly involves synovial joints, and affects up to 1% of adults worldwide. Although the etiology of RA is not fully understood, it has a genetic component.

Interleukin 1 (IL-1) is secreted by activated macrophages in inflamed synovium and initiates the recruitment of immune cells and inflammation. Studies have revealed that 2 single-nucleotide polymorphisms (SNP) at positions –511 and +3954 of the *IL-1B* gene and a variable number of tandem repeats (VNTR) in the second intron of IL-1 receptor antagonist (IL-1RA) are associated with increased risk of autoimmune disease development. *IL-1* polymorphisms have been reported to be associated with RA susceptibility in some studies, showing mixed results^{1–17}. The aim of our study was to determine whether *IL-1* polymorphisms confer susceptibility to RA, and to identify the polymorphisms concerned.

MATERIALS AND METHODS

Identification of eligible studies and data extraction. We searched for studies that examined the associations between IL-1 polymorphisms and RA.

From the Division of Rheumatology, Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea.

Y.H. Lee, MD; J.D. Ji, MD; G.G. Song, MD, Division of Rheumatology, Department of Internal Medicine, Korea University Medical Center.

Address reprint requests to Dr. Y.H. Lee, Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 126-1 ga, Anam-dong, Seongbuk-gu, Seoul, 136-705, Korea. E-mail: lyhcggh@korea.ac.kr

Accepted for publication August 20, 2008.

The Medline citation index was used to identify articles in which IL-1 polymorphisms were analyzed in patients with RA (up to March 2008). In addition, combinations of key words, such as “Interleukin 1,” “IL-1,” “polymorphism,” “rheumatoid arthritis,” and “RA” were entered as both Medical Subject Heading (MeSH) and text words. References in the studies identified were also investigated to identify additional studies not indexed by Medline. Genetic association studies that determined the distributions of IL-1 genotypes in RA cases and controls were eligible for inclusion.

Evaluations of statistical associations. We assessed within- and between-study variations and heterogeneities using Cochran’s Q-statistics and I^2 values. We evaluated publication bias using Egger’s linear regression test. Statistical manipulations were undertaken using a Comprehensive Meta-Analysis computer program (Biostat, Englewood, NJ, USA).

RESULTS

Studies included in the metaanalysis. We identified 63 studies by electronic and manual searches and 19 were selected for full text review based on titles and abstracts. Two studies were excluded due to no extractable data, and data on only one *IL-1A* intron 6 polymorphism, respectively. A total of 17 relevant studies met the study inclusion criteria^{1–17}. One of the eligible studies contained data on 2 different RA groups, and these were treated separately. Therefore, a total of 18 separate studies were considered on 10 European, 7 Asian, and 1 Latin American population samples (Table 1).

Due to the limited number of studies on some polymorphisms, 3 types of metaanalyses were performed on the *IL-1B-511* (*rs16944*), *IL-1B+3954* (*rs1143634*), and *IL-1RN VNTR* polymorphisms (Table 1). Some studies did not give complete genotype data (Table 2), so there was a difference in study numbers in different genetic models.

Metaanalysis of the IL-1B-511 polymorphism and RA sus-

Table 1. Characteristics of individual studies included in meta analysis.

Study	Country (Ethnicity)	Numbers, RA/Controls	IL-1 Polymorphism(s)	Major Findings for Association
Kobayashi ¹	Japan (A)	100/100	IL-1A+4845, IL-1B+3954, IL-RN+2018	IL-1B+3954 (association p = 0.03)
You ²	China (A)	240/227	IL-1B-511, IL-1B+3954, IL-1RN VNTR	IL-1B+3954 C/T (p < 0.001), IL-1RN 2 allele (p = 0.028)
Arman ³	Turkey (A)	94/104	IL-1B-511, IL-1B+3954, IL-1RN VNTR	IL-1B-511 C/T (p = 0.038), IL-1B+3954 T/T (p = 0.028), T allele (p = 0.011)
Kazkaz 1 ⁴	France (E)	512/471	IL-1B+3954, IL-1RN+2018	NS
Kazkaz 2 ⁴	Syria (A)	156/120	IL-1B+3954, IL-1RN+2018	NS
Tolusso ⁵	Italy (E)	126/178	IL-1B-511, IL-1B+3954, IL-1RN VNTR	NS
Grover ⁶	India (A)	107/111	IL-1RN VNTR	NS
Pawlik ⁷	Poland (E)	93/102	IL-1B+3954	NS
Camargo ⁸	Colombia (LA)	172/392	IL-1B-511, IL-1B+3954	NS
Lee ⁹	Korea (A)	138/127	IL-1RN VNTR	2 allele: OR 0.34 (p = 0.024)
Martinez ¹⁰	Spain (E)	229/371	IL-1RN VNTR	NS
Genevay ¹¹	UK (E)	233/148	IL-1A+4845, IL-1B-511, IL-1B+3954, IL-1RN+2016	NS
Kaijzel ¹²	Netherlands (E)	407/245	IL-1A+4845, IL-1B-511, IL-1B+3954, IL-1RN+2016	NS
Cvetkovic ¹³	Sweden (E)	154/202	IL-1RN VNTR	NS
Huang ¹⁴	Taiwan (A)	104/103	IL-1B-511, IL-1B+3954, IL-1RN VNTR	NS
Buchs ¹⁵	France (E)	272/110	IL-1B-511	NS
Cantagrel ⁶	France (E)	106/110	IL-1B-511, IL-1B+3954, IL-1RN VNTR	NS
Perrier ¹⁷	France (E)	43/100	IL-1RN VNTR	NS

E: European; A: Asian; LA: Latin American; UK: United Kingdom; NS: not significant.

Table 2. Meta analysis of IL-1B-511 and IL-1B+3954 polymorphisms and RA association.

Polymorphism	Population	No. of Studies	OR	Test of Association			Test of Heterogeneity		
				95% CI	p	Model	Q	p	I ²
IL-1B-511 C vs T	Overall	8	1.046	0.934–1.172	0.436	F	9.40	0.225	25.5
	Asian*	3	1.037	0.857–1.253	0.711	F	3.19	0.202	37.4
	European	4	1.158	0.975–1.374	0.094	F	2.33	0.505	0
CC vs CT+TT (Recessive)	Overall	8	1.136	0.865–1.492	0.357	R	17.8	0.013	60.8
	Asian*	3	1.201	0.631–2.285	0.576	R	8.52	0.014	76.5
	European	4	1.251	0.994–1.575	0.056	F	3.26	0.353	8.02
CC+CT vs TT (Dominant)	Overall	8	1.019	0.829–1.252	0.859	F	1.58	0.979	0
	Asian*	3	0.955	0.729–1.359	0.977	F	0.29	0.863	0
	European	4	1.105	0.770–1.586	0.589	F	0.98	0.806	0
CC vs TT	Overall	8	1.007	0.792–1.282	0.952	F	6.22	0.514	0
	Asian*	3	0.962	0.656–1.412	0.844	F	2.00	0.367	0.30
	European	4	1.260	0.859–1.846	0.237	F	1.27	0.735	0
IL-1B+3954 C vs T	Overall	10	0.798	0.628–1.015	0.066	R	25.5	0.002	64.8
	Asian*	4	0.489	0.357–0.669	< 0.001	F	5.2	0.151	43.3
	European	5	0.869	0.740–1.020	0.086	F	3.22	0.521	0
CC vs CT+TT (Recessive)	Overall	10	0.776	0.609–0.988	0.040	R	18.8	0.027	52.1
	Asian*	4	0.496	0.346–0.710	≤ 0.001	F	6.08	0.108	50.6
	European	5	0.832	0.677–1.001	0.051	F	1.49	0.827	0
CC+CT vs TT (Dominant)	Overall	8	0.836	0.507–1.380	0.484	R	13.7	0.055	49.2
	Asian*	2	0.286	0.118–0.691	0.005	F	0.06	0.804	0
	European	5	0.933	0.620–1.404	0.741	F	5.06	0.281	21.0
CC vs TT	Overall	8	0.789	0.470–1.325	0.370	R	14.3	0.046	51.1
	Asian*	2	0.263	0.108–0.645	0.003	F	0.03	0.852	0
	European	5	0.867	0.572–1.314	0.501	F	5.00	0.287	20.0
CT vs TT	Overall	8	0.938	0.685–1.412	0.926	F	10.0	0.184	30.5
	Asian*	2	0.404	0.158–1.033	0.058	F	0.81	0.365	0
	European	5	1.660	0.635–4.341	0.301	F	0.30	0.10	0

* Some studies did not give complete genotype data. F: fixed effect model; R: random effect model.




Figure 1. Odds ratios and 95% confidence intervals of individual studies and pooled data for the *IL-1B+3954* CC and CT+TT genotypes (recessive model) for susceptibility to RA in Asians and Europeans.

ceptibility. Metaanalysis identified no association between RA and *IL-1B-511* C allele in the overall population (OR 1.046, 95% CI 0.934–1.172, $p = 0.436$; Table 2). Further, stratification by ethnicity failed to identify any association between this polymorphism and RA in the European or Asian groups (Table 2).

Metaanalysis of the *IL-1B+3954* polymorphism and RA susceptibility. Metaanalysis revealed a significantly greater association between the CC genotype and the risk of developing RA than between the CT+TT genotype and RA (OR 0.776, 95% CI 0.609–0.988, $p = 0.040$), but with between-study heterogeneity ($p = 0.027$; Table 2). In Asians, an associational difference was found between the CC genotype and the CT+TT genotype (OR 0.496, 95% CI 0.346–0.710, $p < 0.001$; Figure 1). A measure consisting of the ratio of $\log OR_{CT}$ versus $\log OR_{CC}$ was 0.67, which suggests a codominant mode of action. However, in Europeans, no association was found between the *IL-1B+3954* polymorphism and RA susceptibility.

Metaanalysis of the *IL-1RN VNTR* versus RA association. No association was found between RA susceptibility and *IL-1RN VNTR* by metaanalyses.

DISCUSSION

Our findings do not support associations between the *IL-1B-511* and *IL-1RN VNTR* polymorphisms and RA susceptibility. Further, although heterogeneity was found among studies, no association was found between the *IL-1B-511* or *IL-1RN VNTR* polymorphisms and RA susceptibility. In contrast, metaanalysis of the *IL-1B+3954* polymorphism revealed that the CC genotype was more associated with the

risk of developing RA than the CT+TT genotype. In particular, in Asians, an association between the CC genotype and RA was observed, but this was not evident in Europeans. These findings suggest that the *IL-1B+3954* polymorphism is associated with development of RA in Asians but not in Europeans. However, in the European populations, recessive and allele contrast analyses showed that the *IL-1B+3954* polymorphism tended to be associated with RA susceptibility, and thus the possibility that the *IL-1B+3954* polymorphism plays a role in the pathogenesis of RA in Europeans cannot be ruled out.

Our study has some limitations that should be considered. First, heterogeneity and small sample size may have distorted the metaanalysis, but most heterogeneity was resolved by ethnic-specific subgroup analysis. Second, ethnic-specific metaanalysis included data from European and Asian patients, and thus our results are applicable only to these ethnic groups. Third, there was only a handful of studies in Asian populations and complete genotype data were not available from 2 Asian studies.

This metaanalysis of published data identified that the *IL-1B+3954* polymorphism was associated with RA in Asians.

REFERENCES

1. Kobayashi T, Ito S, Kuroda T, et al. The interleukin-1 and Fc-gamma receptor gene polymorphisms in Japanese patients with rheumatoid arthritis and periodontitis. *J Periodontol* 2007;78:2311-8.
2. You CG, Li JF, Xie XD, Zhu Y, Li PQ, Chen YR. Association of interleukin-1 genetic polymorphisms with the risk of rheumatoid arthritis in Chinese population. *Clin Chem Lab Med* 2007;45:968-71.
3. Arman A, Yilmaz B, Coker A, Inanc N, Direskeneli H.

- Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2006;24:643-8.
4. Kazkaz L, Marotte H, Hamwi M, et al. Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. *Ann Rheum Dis* 2007;66:195-201.
 5. Tolusso B, Pietrapertosa D, Morelli A, et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. *Pharmacogenomics* 2006;7:683-95.
 6. Grover S, Tandon S, Misra R, Aggarwal A. Interleukin-1 receptor antagonist gene polymorphism in patients with rheumatoid arthritis in India. *Indian J Med Res* 2006;123:815-20.
 7. Pawlik A, Kurzawski M, Florczak M, Gawronska Szklarz B, Herczynska M. IL1 beta+3953 exon 5 and IL-2 -330 promoter polymorphisms in patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2005;23:159-64.
 8. Camargo JF, Correa PA, Castiblanco J, Anaya JM. Interleukin-1 beta polymorphisms in Colombian patients with autoimmune rheumatic diseases. *Genes Immun* 2004;5:609-14.
 9. Lee YH, Kim HJ, Rho YH, Choi SJ, Ji JD, Song GG. Interleukin-1 receptor antagonist gene polymorphism and rheumatoid arthritis. *Rheumatol Int* 2004;24:133-6.
 10. Martinez A, Pascual M, Pascual-Salcedo D, Balsa A, Martin J, de la Concha EG. Genetic polymorphisms in Spanish rheumatoid arthritis patients: an association and linkage study. *Genes Immun* 2003;4:117-21.
 11. Genevay S, di Giovine FS, Perneger TV, et al. Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. *Arthritis Rheum* 2002;47:303-9.
 12. Kaijzel EL, van Dongen H, Bakker AM, Breedveld FC, Huizinga TW, Verweij CL. Relationship of polymorphisms of the interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis. *Tissue Antigens* 2002;59:122-6.
 13. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Lefvert AK. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-a, IL-1B, and IL-1Ra genes. *J Rheumatol* 2002;29:212-9.
 14. Huang CM, Tsai FJ, Wu JY, Wu MC. Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in rheumatoid arthritis. *Scand J Rheumatol* 2001;30:225-8.
 15. Buchs N, di Giovine FS, Silvestri T, Vannier E, Duff GW, Miossec P. IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. *Genes Immun* 2001;2:222-8.
 16. Cantagrel A, Navaux F, Loubet-Lescoulie P, et al. Interleukin-1B, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. *Arthritis Rheum* 1999;42:1093-100.
 17. Perrier S, Coussediere C, Dubost JJ, Albuissou E, Sauvezie B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjogren's syndrome and rheumatoid arthritis. *Clin Immunol Immunopathol* 1998;87:309-13.